{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:46:21Z","timestamp":1791971181494,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:00:00Z","timestamp":1791676800000},"content-version":"vor","delay-in-days":283,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101482","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:36:54Z","timestamp":1791956214000},"page":"101482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Emerging immunotherapies in melanoma beyond immune checkpoint inhibitors: Vaccines, intralesional therapies, adoptive cell therapies, and T-cell engagers"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7160-8812","authenticated-orcid":false,"given":"Ida","family":"Taglialatela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Di Corcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5336-5578","authenticated-orcid":false,"given":"Andrea","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sponghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Esposto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Farinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giorgione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Zottarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Zavattaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Savoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gennari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ctarc.2026.101482_bib0001","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study","volume":"35","author":"Long","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101482_bib0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101482_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115547","article-title":"Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update","volume":"225","author":"Lipson","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101482_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114327","article-title":"Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325\/KEYNOTE-054 trial","volume":"211","author":"Eggermont","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"17","key":"10.1016\/j.ctarc.2026.101482_bib0005","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238","volume":"29","author":"Larkin","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.ctarc.2026.101482_bib0006","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","article-title":"Final results for adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"391","author":"Long","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101482_bib0007","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert. Rev. AntiCancer Ther."},{"issue":"32","key":"10.1016\/j.ctarc.2026.101482_bib0008","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.22.00202","article-title":"Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts: implications for adjuvant treatment","volume":"40","author":"Garbe","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.ctarc.2026.101482_bib0009","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.23.02355","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study","volume":"42","author":"Luke","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101482_bib0010","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101482_bib0011","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.22.00533","article-title":"Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915)","volume":"41","author":"Weber","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101482_bib0012","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1038\/s41591-025-04032-8","article-title":"Adjuvant nivolumab and relatlimab in stage III\/IV melanoma: the randomized phase 3 RELATIVITY-098 trial","volume":"31","author":"Long","year":"2025","journal-title":"Nat. Med."},{"issue":"27","key":"10.1016\/j.ctarc.2026.101482_bib0013","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1080\/14796694.2024.2343272","article-title":"The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies","volume":"20","author":"Shapira-Frommer","year":"2024","journal-title":"Future Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101482_bib0014","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2217\/fon-2021-1286","article-title":"PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III\/IV melanoma at high risk for recurrence","volume":"18","author":"Eggermont","year":"2022","journal-title":"Future Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101482_bib0015","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","article-title":"Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study","volume":"22","author":"Pires da Silva","year":"2021","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101482_bib0016","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(18)30353-X","article-title":"Negative but not futile: MAGE-A3 immunotherapeutic for melanoma","volume":"19","author":"Daud","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101482_bib0017","series-title":"EVX-01, a personalized cancer vaccine, induces potent T-cell responses and durable disease control in advanced melanoma: 2-year follow-up. Presented at: 2025 ESMO Congress","author":"Khattak","year":"2025"},{"issue":"10427","key":"10.1016\/j.ctarc.2026.101482_bib0018","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101482_bib0019","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.annonc.2025.06.014","article-title":"Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma","volume":"36","author":"K\u00e4hler","year":"2025","journal-title":"Ann. Oncol."},{"issue":"28","key":"10.1016\/j.ctarc.2026.101482_bib0020","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1200\/JCO-26-00852","article-title":"Neoadjuvant intralesional daromun (L19IL2\/L19TNF) in resectable locally advanced melanoma: an update on the efficacy and safety results of the PIVOTAL phase III trial","volume":"44","author":"Hauschild","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.ctarc.2026.101482_bib0021","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1200\/JCO-25-01346","article-title":"RP1 combined with nivolumab in advanced anti-PD-1-failed melanoma (IGNYTE)","volume":"43","author":"Wong","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101482_bib0023","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12967-025-06093-2","article-title":"Application of adoptive cell therapy in malignant melanoma","volume":"23","author":"Hu","year":"2025","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101482_bib0024","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_431608","article-title":"Adoptive cell therapy for solid tumors: current status in melanoma and next-generation therapies","volume":"44","author":"Haanen","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"24","key":"10.1016\/j.ctarc.2026.101482_bib0025","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101482_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte therapy, in patients with advanced melanoma: results from the C-144-01 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J. ImmunOther Cancer"},{"issue":"33","key":"10.1016\/j.ctarc.2026.101482_bib0027","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1200\/JCO-25-00765","article-title":"Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte cell therapy in patients with advanced melanoma: a 5-year analysis of the C-144-01 study","volume":"43","author":"Medina","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.ctarc.2026.101482_bib0028","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1158\/1078-0432.CCR-25-0880","article-title":"FDA approval summary: lifileucel for unresectable or metastatic melanoma previously treated with an anti-PD-1-based immunotherapy","volume":"31","author":"Hu","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2026.101482_bib0029","doi-asserted-by":"crossref","first-page":"9519","DOI":"10.1200\/JCO.2025.43.16_suppl.9519","article-title":"OBX-115 engineered tumor-infiltrating lymphocytes (TIL) with regulatable membrane-bound IL15 (mbIL15): translational data from a single-center phase 1 trial in patients (pts) with immune checkpoint inhibitor (ICI)\u2013resistant advanced melanoma","volume":"43","author":"Amaria","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2026.101482_bib0030","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1200\/JCO.2026.44.16_suppl.9508","article-title":"Patient-level clinical response dynamics in advanced melanoma with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy","volume":"44","author":"Davar","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"suppl 2","key":"10.1016\/j.ctarc.2026.101482_bib0031","first-page":"S882","article-title":"Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma","volume":"36","author":"Patel","year":"2025","journal-title":"Ann. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2026.101482_bib0032","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2025.43.16_suppl.2508","article-title":"Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma","volume":"43","author":"Wermke","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101482_bib0033","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","article-title":"The emerging landscape of immune cell therapies","volume":"181","author":"Weber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2026.101482_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ctarc.2026.101482_bib0035","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","article-title":"T cell engagers: expanding horizons in oncology and beyond","volume":"133","author":"Albayrak","year":"2025","journal-title":"Br. J. Cancer"},{"issue":"13","key":"10.1016\/j.ctarc.2026.101482_bib0036","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.ctarc.2026.101482_bib0037","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101482_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006747","article-title":"Tebentafusp in combination with durvalumab and\/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study","volume":"11","author":"Hamid","year":"2023","journal-title":"J. ImmunOther Cancer"},{"key":"10.1016\/j.ctarc.2026.101482_bib0039","unstructured":"ClinicalTrials.gov. Tebentafusp regimen versus investigator\u2019s choice in previously treated advanced melanoma (TEBE-AM). NCT05549297. Accessed December 29, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05549297."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101482_bib0040","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.3390\/biomedicines13081988","article-title":"Therapeutic opportunities in melanoma through PRAME expression","volume":"13","author":"Mokos","year":"2025","journal-title":"Biomedicines"},{"issue":"suppl","key":"10.1016\/j.ctarc.2026.101482_bib0041","article-title":"Phase 1 safety and efficacy of brenetafusp, a PRAME\u202f\u00d7\u202fCD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM)","volume":"12","author":"Davar","year":"2024","journal-title":"J. ImmunOther Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101482_bib0042","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","article-title":"Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann. Oncol."},{"issue":"6371","key":"10.1016\/j.ctarc.2026.101482_bib0043","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ctarc.2026.101482_bib0044","unstructured":"ClinicalTrials.gov. PIP-PREDICT: prospective implementation of predictive biomarker reports in melanoma (NCT06536257). Accessed October 10, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06536257."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:52:49Z","timestamp":1791967969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":43,"alternative-id":["S2468294226003916"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101482","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging immunotherapies in melanoma beyond immune checkpoint inhibitors: Vaccines, intralesional therapies, adoptive cell therapies, and T-cell engagers","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101482","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101482"}}